Al18F-NOTA-octreotide

DRUG2 trials

Sponsors

Universitaire Ziekenhuizen KU Leuven

Conditions

Neuroendocrine Tumors

Phase 1

Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors

CompletedNCT03883776

Universitaire Ziekenhuizen KU LeuvenNeuroendocrine Tumors

Start: 2019-04-11End: 2019-10-29Updated: 2020-09-09

Phase 2

Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors

CompletedNCT04552847

Universitaire Ziekenhuizen KU LeuvenNeuroendocrine Tumors

Start: 2020-10-07End: 2022-02-08Updated: 2022-02-17

Related Papers

Comparison of inter- and intraobserver agreement between [<sup>18</sup>F]AlF-NOTA-octreotide and [<sup>68</sup>Ga]Ga-DOTA-SSA PET/CT.

2025-05-151 citations

Clinical impact of using [ <scp> <sup>18</sup> F </scp> ] <scp>AlF</scp> ‐ <scp>NOTA</scp> ‐octreotide <scp>PET</scp> / <scp>CT</scp> instead of [ <scp> <sup>68</sup> Ga </scp> ]Ga‐ <scp>DOTA</scp> ‐ <scp>SSA PET</scp> / <scp>CT</scp> : Secondary endpoint analysis of a multicenter, prospective trial

Journal of Neuroendocrinology2024-06-047 citations

Prospective comparison of [<sup>18</sup>F]AlF-NOTA-octreotide PET/MRI to [<sup>68</sup>Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients.

2023-06-0112 citations

<sup>18</sup>F-AlF-NOTA-Octreotide Outperforms<sup>68</sup>Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study

Journal of Nuclear Medicine2022-10-2062 citations

[<sup>18</sup>F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [<sup>68</sup>Ga]Ga-DOTATATE in neuroendocrine tumour patients.

2020-07-0265 citations